Article Figures & Data
Figures
- Figure 1.
Kaplan–Meier analysis showing progression-free survival (PFS) for patients with non-squamous non-small-cell lung cancer treated with bevacizumab in combination with docetaxel or pemetrexed. The median PFS (mPFS) was 5.0 months [95% confidence interval (CI)=3.2-8.8 months] (A), and there was no significant difference in PFS between patients treated in the second-line (mPFS=6.4 months, 95% CI=1.4-16.1 months) and third-line setting or later (mPFS=4.9 months, 95% CI=3.0-7.0 months) (B).
- Figure 2.
Kaplan–Meier analysis showing overall survival for patients with non-squamous non-small-cell lung cancer treated with bevacizumab in combination with docetaxel or pemetrexed. The median survival duration was 15.8 months (95% confidence interval=10.5-19.6 months).
